Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …

Alkylating agents have been used since the 60ties in brain cancer chemotherapy. Their
target is the DNA and, although the DNA of normal and cancer cells is damaged …

Background A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both
within and between tumors. This variability causes a risk for sampling bias and potential …

Epigenetic patterns, such as DNA methylation, histone modifications, and non-coding RNAs,
can be both driver factors and characteristic features of certain malignancies. Aberrant DNA …

BACKGROUND Spinal cord glioma grade IV is a rare, diffuse midline glioma. H3 K27M-
mutant was classified in a different entity in the 2016 World Health Organization (WHO) …

DNA repair represents the first barrier against genotoxic stress causing metabolic changes,
inflammation and cancer. Besides its role in preventing cancer, DNA repair needs also to be …

Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant
glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer. The drug …

Colorectal carcinogenesis is a multistep process involving the accumulation of genetic
alterations over time that ultimately leads to disease progression and metastasis. Binding of …

BACKGROUND Previous studies addressing the influence of surgery on the outcome of
patients with glioblastomas (GBM) have not addressed molecular markers. The value of …

Patients suffering from glioblastoma have a dismal prognosis, indicating the need for new
therapeutic targets. Here we provide evidence that the DNA damage kinase HIPK2 and its …